Meridian Bioscience, Inc. (VIVO) Enters into Product Development and Distribution Agreement with DiaSorin S.p.A.  
7/7/2010 10:41:06 AM

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has entered into an exclusive, world-wide product development and distribution agreement with DiaSorin S.p.A. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop several infectious disease products for use on their LIAISONĀ® systems. LIAISON is a fully automated, random access system based on chemiluminescense detection. There are over 3,000 LIAISON systems placed in laboratories throughout the world. The agreement is royalty-based with the actual royalty amount to be paid to Meridian dependent on type of test and specific geographic market.